Teva Pharmaceuticals USA Inc has recalled 1,565 vials of IDArubicin Hydrochloride Injection USP (5mg/5mL) after finding particulate matter inside the product. Specifically, the injection was found to contain silica and iron oxide, which should not be present in a sterile injectable drug. This recall affects 5mL single-dose vials from lot 31329657B with an expiration date of August 2023. No incidents or injuries have been reported to date.
Injecting a drug containing silica and iron oxide particles can cause serious health complications, such as inflammation, allergic reactions, or blood vessel blockages that may lead to organ damage. Because this medication is administered intravenously, the presence of foreign particles poses a critical risk to patient safety.
Recall #: D-0765-2022; Quantity: 1565 vials
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.